Research programme: recombinant Fc multimer proteins - Momenta Pharmaceuticals

Drug Profile

Research programme: recombinant Fc multimer proteins - Momenta Pharmaceuticals

Latest Information Update: 28 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Momenta Pharmaceuticals
  • Class Immunoglobulin Fc fragments; Recombinant proteins
  • Mechanism of Action Fc receptor modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Autoimmune disorders

Highest Development Phases

  • Preclinical Autoimmune disorders

Most Recent Events

  • 28 Feb 2018 CSL and Momenta Pharmaceuticals are developing additional recombinant Fc multimer proteins (Momenta Pharmaceuticals website, February 2018)
  • 01 Dec 2014 Preclinical trials in Autoimmune disorders in USA (Parenteral) prior to December 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top